Biden Decriminalizes Cannabis

A

ActionianJacksonian

Well-Known Member
PJ Diaz said:
This has nothing to do with that. I voted for Biden. He said that he was gonna legalize weed. So far, he's arrested more peeps than before. Winning?
Click to expand...
Yep, Code of Federal Regulations is squarely in the Executive Branch, who still to this day grow, package and deliver weed to medicinal patients.
 
lilroach

lilroach

Well-Known Member
I'm not sure Biden can actually decriminalize weed. The Senate makes the laws. The DEC is the one that keeps it on the federal narcotics list.

Big Pharma wants it illegal.....Congress talks big, but never gets it done.
 
PJ Diaz

PJ Diaz

Well-Known Member
lilroach said:
I'm not sure Biden can actually decriminalize weed. The Senate makes the laws. The DEC is the one that keeps it on the federal narcotics list.

Big Pharma wants it illegal.....Congress talks big, but never gets it done.
Click to expand...
www.marijuanamoment.net

Biden Administration Can Legalize Marijuana Without Waiting For Lawmakers, Congressional Researchers Say

President Joe Biden can grant mass amnesty to people who have violated federal marijuana laws, congressional researchers said in a new report, adding that his administration can also move to federally legalize cannabis without waiting for lawmakers to act. The new analysis published by the...
www.marijuanamoment.net www.marijuanamoment.net
 
cannabineer

cannabineer

Ursus marijanus
lilroach said:
I'm not sure Biden can actually decriminalize weed. The Senate makes the laws. The DEC is the one that keeps it on the federal narcotics list.

Big Pharma wants it illegal.....Congress talks big, but never gets it done.
Click to expand...
Big pharma does not care.
Their big money is made by treating conditions that weed doesn’t significantly affect.
 
PJ Diaz

PJ Diaz

Well-Known Member
cannabineer said:
not on a phone
Click to expand...
BY LZ GRANDERSONCOLUMNIST
APRIL 20, 2022 3:15 AM PT
Before I start talking about pot and why the federal prohibition should end, here are some numbers for you to consider.
Seventy-two U.S. senators accepted donations from the pharmaceutical industry ahead of the 2020 election. That number was 302 for the House. Combined, that’s more than two-thirds of Congress.
If that makes you sick to your stomach, you might want to sit down for this: More than 2,400 state legislators around the country cashed checks from drug lobbyists, including 82% of state lawmakers in California, which has a deep blue legislature. That’s on par with 84% of lawmakers in Louisiana, a state redder than Mississippi, in case you are tempted to see this as a partisan problem.
In 2021, the lobbying industry broke its overall record — eclipsing $3.7 billion — with experts pointing to Congress’ renewed effort to lower prescription costs as the primary driver behind the spike in pharma spending. Apparently, some people are happy with the status quo and are willing to fight for it.

For the rest of us, a recent study from Cornell University might offer some relief. Researchers looked at Medicaid prescription data between 2011 and 2019 and found there was a decline in drug usage among Medicaid enrollees with access to recreational marijuana. We’re talking drugs to treat pain, depression, anxiety or help with sleeping, you know, the kind with television commercials.


The report, published in the Health Economics journal on Good Friday (do with that what you will), said that its “results suggest substitution away from prescription drugs and potential cost savings for state Medicaid programs.”
I wonder how Big Pharma took the news. It is already spending more than any other industry to fight cost-cutting measures. Now every marijuana dispensary or grower in America is potentially a threat.
Shyam Raman, one of the study’s researchers, also said the results “indicate an opportunity to reduce the harm that can come with the dangerous side effects associated with some prescription drugs.” (Think about that laundry list of awful side effects we typically hear at the end of those commercials.)


Yes, it’s important to point out that just because an elected official accepts money from lobbyists doesn’t automatically mean they are in anyone’s pocket. It is also important to point out that lobbyists don’t donate money in hopes of having less influence.
Maybe it’s just misfortune that prescription drug spending in the U.S. is about twice that of comparable nations, according to the Organization for Economic Cooperation and Development. Maybe it’s just luck that for 17 of the world’s top 20 prescription drugs, pharmaceutical companies made more from U.S. sales than sales from all the other countries combined. Or maybe making donations to more than 60% of members of Congress has its benefits.
The question now is: How much more is Big Pharma willing to spend to keep things as they are? In 1960, national health expenditures represented 5% of GDP. Today, it’s at an all-time high of 19.7%. Last September, when the Democrats’ proposal to cut prices faltered in a House committee, two of the three moderates who voted against it received more than $100,000 each from the drug lobby, according to a Stat analysis.
Back to pot.
Earlier this month the House passed the MORE Act, a bill that would remove marijuana from the list of banned controlled substances, thus ending prohibition. It passed 220 to 204, mostly along party lines. The last time the bill passed the House, the Senate did not take it up. This time Senate Majority Leader Chuck Schumer had promised to file his draft legislation to end prohibition — the Cannabis Administration and Opportunity Act — in April, but now says he will do so before the August recess, presumably to either try to gain more support or use it as an election issue for the midterms. Regardless of when it’s introduced, it’s doubtful 10 Senate Republicans will support the effort.
This is why we should be keeping our eyes on the money. Big Pharma was already on red alert with rumblings of price-cutting legislation. Now on the heels of studies that found a drop in prescription drug usage among Medicare enrollees with access to medical marijuana comes a report of a similar pattern in recreational usage. Ending prohibition could pose a significant challenge to drug industry leaders with shareholders consumed with the bottom line. Could this be part of the reason why Congress is in no rush to do so?
 
cannabineer

cannabineer

Ursus marijanus
PJ Diaz said:
BY LZ GRANDERSONCOLUMNIST
APRIL 20, 2022 3:15 AM PT
Before I start talking about pot and why the federal prohibition should end, here are some numbers for you to consider.
Seventy-two U.S. senators accepted donations from the pharmaceutical industry ahead of the 2020 election. That number was 302 for the House. Combined, that’s more than two-thirds of Congress.
If that makes you sick to your stomach, you might want to sit down for this: More than 2,400 state legislators around the country cashed checks from drug lobbyists, including 82% of state lawmakers in California, which has a deep blue legislature. That’s on par with 84% of lawmakers in Louisiana, a state redder than Mississippi, in case you are tempted to see this as a partisan problem.
In 2021, the lobbying industry broke its overall record — eclipsing $3.7 billion — with experts pointing to Congress’ renewed effort to lower prescription costs as the primary driver behind the spike in pharma spending. Apparently, some people are happy with the status quo and are willing to fight for it.

For the rest of us, a recent study from Cornell University might offer some relief. Researchers looked at Medicaid prescription data between 2011 and 2019 and found there was a decline in drug usage among Medicaid enrollees with access to recreational marijuana. We’re talking drugs to treat pain, depression, anxiety or help with sleeping, you know, the kind with television commercials.


The report, published in the Health Economics journal on Good Friday (do with that what you will), said that its “results suggest substitution away from prescription drugs and potential cost savings for state Medicaid programs.”
I wonder how Big Pharma took the news. It is already spending more than any other industry to fight cost-cutting measures. Now every marijuana dispensary or grower in America is potentially a threat.
Shyam Raman, one of the study’s researchers, also said the results “indicate an opportunity to reduce the harm that can come with the dangerous side effects associated with some prescription drugs.” (Think about that laundry list of awful side effects we typically hear at the end of those commercials.)


Yes, it’s important to point out that just because an elected official accepts money from lobbyists doesn’t automatically mean they are in anyone’s pocket. It is also important to point out that lobbyists don’t donate money in hopes of having less influence.
Maybe it’s just misfortune that prescription drug spending in the U.S. is about twice that of comparable nations, according to the Organization for Economic Cooperation and Development. Maybe it’s just luck that for 17 of the world’s top 20 prescription drugs, pharmaceutical companies made more from U.S. sales than sales from all the other countries combined. Or maybe making donations to more than 60% of members of Congress has its benefits.
The question now is: How much more is Big Pharma willing to spend to keep things as they are? In 1960, national health expenditures represented 5% of GDP. Today, it’s at an all-time high of 19.7%. Last September, when the Democrats’ proposal to cut prices faltered in a House committee, two of the three moderates who voted against it received more than $100,000 each from the drug lobby, according to a Stat analysis.
Back to pot.
Earlier this month the House passed the MORE Act, a bill that would remove marijuana from the list of banned controlled substances, thus ending prohibition. It passed 220 to 204, mostly along party lines. The last time the bill passed the House, the Senate did not take it up. This time Senate Majority Leader Chuck Schumer had promised to file his draft legislation to end prohibition — the Cannabis Administration and Opportunity Act — in April, but now says he will do so before the August recess, presumably to either try to gain more support or use it as an election issue for the midterms. Regardless of when it’s introduced, it’s doubtful 10 Senate Republicans will support the effort.
This is why we should be keeping our eyes on the money. Big Pharma was already on red alert with rumblings of price-cutting legislation. Now on the heels of studies that found a drop in prescription drug usage among Medicare enrollees with access to medical marijuana comes a report of a similar pattern in recreational usage. Ending prohibition could pose a significant challenge to drug industry leaders with shareholders consumed with the bottom line. Could this be part of the reason why Congress is in no rush to do so?
Click to expand...
Thanks for the text.

When I clicked on the link about the drop in prescription drugs, opioids were again showcased. I’m glad weed works for some people. It never did a thing for my migraines. And you won’t see me arguing that opioids are not a racket.

I would be more impressed if using weed saved on nonpsychoactives e. g. hypertension meds, antidiabetics and antibiotics. Those are bigger cash cows than opioids iirc.
 
PJ Diaz

PJ Diaz

Well-Known Member
cannabineer said:
Thanks for the text.

When I clicked on the link about the drop in prescription drugs, opioids were again showcased. I’m glad weed works for some people. It never did a thing for my migraines. And you won’t see me arguing that opioids are not a racket.

I would be more impressed if using weed saved on nonpsychoactives e. g. hypertension meds, antidiabetics and antibiotics. Those are bigger cash cows than opioids iirc.
Click to expand...
www.theguardian.com

How cannabis-fed chickens may help cut Thai farmers’ antibiotic use

Scientists observed fewer cases of avian bronchitis and superior meat after chickens given cannabis
www.theguardian.com www.theguardian.com

norml.org

Study: CBG Administration Lowers Blood Pressure in Preclinical Model

Researchers determined, “These findings add to the growing literature regarding the role of cannabinoids in blood pressure regulation.”
norml.org norml.org

www.healthline.com

Is Marijuana A Good Option For Treating Diabetes?

Backed by medical research, marijuana can actually treat diabetes - not just soften the symptoms - some call it a "medical super-miracle."
www.healthline.com www.healthline.com
 
cannabineer

cannabineer

Ursus marijanus
PJ Diaz said:
www.theguardian.com

How cannabis-fed chickens may help cut Thai farmers’ antibiotic use

Scientists observed fewer cases of avian bronchitis and superior meat after chickens given cannabis
www.theguardian.com www.theguardian.com

norml.org

Study: CBG Administration Lowers Blood Pressure in Preclinical Model

Researchers determined, “These findings add to the growing literature regarding the role of cannabinoids in blood pressure regulation.”
norml.org norml.org

www.healthline.com

Is Marijuana A Good Option For Treating Diabetes?

Backed by medical research, marijuana can actually treat diabetes - not just soften the symptoms - some call it a "medical super-miracle."
www.healthline.com www.healthline.com
Click to expand...
one day we will be able to do clinical trials.
 
Dorian2

Dorian2

Well-Known Member
PJ Diaz said:
BY LZ GRANDERSONCOLUMNIST
APRIL 20, 2022 3:15 AM PT
Before I start talking about pot and why the federal prohibition should end, here are some numbers for you to consider.
Seventy-two U.S. senators accepted donations from the pharmaceutical industry ahead of the 2020 election. That number was 302 for the House. Combined, that’s more than two-thirds of Congress.
If that makes you sick to your stomach, you might want to sit down for this: More than 2,400 state legislators around the country cashed checks from drug lobbyists, including 82% of state lawmakers in California, which has a deep blue legislature. That’s on par with 84% of lawmakers in Louisiana, a state redder than Mississippi, in case you are tempted to see this as a partisan problem.
In 2021, the lobbying industry broke its overall record — eclipsing $3.7 billion — with experts pointing to Congress’ renewed effort to lower prescription costs as the primary driver behind the spike in pharma spending. Apparently, some people are happy with the status quo and are willing to fight for it.

For the rest of us, a recent study from Cornell University might offer some relief. Researchers looked at Medicaid prescription data between 2011 and 2019 and found there was a decline in drug usage among Medicaid enrollees with access to recreational marijuana. We’re talking drugs to treat pain, depression, anxiety or help with sleeping, you know, the kind with television commercials.


The report, published in the Health Economics journal on Good Friday (do with that what you will), said that its “results suggest substitution away from prescription drugs and potential cost savings for state Medicaid programs.”
I wonder how Big Pharma took the news. It is already spending more than any other industry to fight cost-cutting measures. Now every marijuana dispensary or grower in America is potentially a threat.
Shyam Raman, one of the study’s researchers, also said the results “indicate an opportunity to reduce the harm that can come with the dangerous side effects associated with some prescription drugs.” (Think about that laundry list of awful side effects we typically hear at the end of those commercials.)


Yes, it’s important to point out that just because an elected official accepts money from lobbyists doesn’t automatically mean they are in anyone’s pocket. It is also important to point out that lobbyists don’t donate money in hopes of having less influence.
Maybe it’s just misfortune that prescription drug spending in the U.S. is about twice that of comparable nations, according to the Organization for Economic Cooperation and Development. Maybe it’s just luck that for 17 of the world’s top 20 prescription drugs, pharmaceutical companies made more from U.S. sales than sales from all the other countries combined. Or maybe making donations to more than 60% of members of Congress has its benefits.
The question now is: How much more is Big Pharma willing to spend to keep things as they are? In 1960, national health expenditures represented 5% of GDP. Today, it’s at an all-time high of 19.7%. Last September, when the Democrats’ proposal to cut prices faltered in a House committee, two of the three moderates who voted against it received more than $100,000 each from the drug lobby, according to a Stat analysis.
Back to pot.
Earlier this month the House passed the MORE Act, a bill that would remove marijuana from the list of banned controlled substances, thus ending prohibition. It passed 220 to 204, mostly along party lines. The last time the bill passed the House, the Senate did not take it up. This time Senate Majority Leader Chuck Schumer had promised to file his draft legislation to end prohibition — the Cannabis Administration and Opportunity Act — in April, but now says he will do so before the August recess, presumably to either try to gain more support or use it as an election issue for the midterms. Regardless of when it’s introduced, it’s doubtful 10 Senate Republicans will support the effort.
This is why we should be keeping our eyes on the money. Big Pharma was already on red alert with rumblings of price-cutting legislation. Now on the heels of studies that found a drop in prescription drug usage among Medicare enrollees with access to medical marijuana comes a report of a similar pattern in recreational usage. Ending prohibition could pose a significant challenge to drug industry leaders with shareholders consumed with the bottom line. Could this be part of the reason why Congress is in no rush to do so?
Click to expand...
;)
 
thumper60

thumper60

Well-Known Member
lilroach said:
I'm not sure Biden can actually decriminalize weed. The Senate makes the laws. The DEC is the one that keeps it on the federal narcotics list.

Big Pharma wants it illegal.....Congress talks big, but never gets it done.
Click to expand...
Big pharma not the only one,police unions are right on top to keep it illegal, along with big textile even big oil is against legal weed.
 
You must log in or register to reply here.
Top